Kodiak Sciences (KOD) Competitors $4.36 +0.20 (+4.81%) Closing price 04/30/2025 04:00 PM EasternExtended Trading$4.46 +0.10 (+2.27%) As of 09:12 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock KOD vs. REPL, NUVB, CRON, PAHC, AVBP, LENZ, EOLS, DNTH, ANAB, and XERSShould you be buying Kodiak Sciences stock or one of its competitors? The main competitors of Kodiak Sciences include Replimune Group (REPL), Nuvation Bio (NUVB), Cronos Group (CRON), Phibro Animal Health (PAHC), ArriVent BioPharma (AVBP), LENZ Therapeutics (LENZ), Evolus (EOLS), Dianthus Therapeutics (DNTH), AnaptysBio (ANAB), and Xeris Biopharma (XERS). These companies are all part of the "pharmaceutical products" industry. Kodiak Sciences vs. Replimune Group Nuvation Bio Cronos Group Phibro Animal Health ArriVent BioPharma LENZ Therapeutics Evolus Dianthus Therapeutics AnaptysBio Xeris Biopharma Kodiak Sciences (NASDAQ:KOD) and Replimune Group (NASDAQ:REPL) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, earnings, community ranking, valuation, risk, media sentiment and analyst recommendations. Do analysts recommend KOD or REPL? Kodiak Sciences currently has a consensus target price of $9.00, indicating a potential upside of 106.42%. Replimune Group has a consensus target price of $19.43, indicating a potential upside of 98.66%. Given Kodiak Sciences' higher probable upside, analysts plainly believe Kodiak Sciences is more favorable than Replimune Group.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kodiak Sciences 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00Replimune Group 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13 Which has preferable valuation and earnings, KOD or REPL? Replimune Group is trading at a lower price-to-earnings ratio than Kodiak Sciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKodiak SciencesN/AN/A-$260.49M-$3.36-1.30Replimune GroupN/AN/A-$215.79M-$3.07-3.19 Does the media prefer KOD or REPL? In the previous week, Kodiak Sciences had 1 more articles in the media than Replimune Group. MarketBeat recorded 6 mentions for Kodiak Sciences and 5 mentions for Replimune Group. Kodiak Sciences' average media sentiment score of 1.48 beat Replimune Group's score of 1.47 indicating that Kodiak Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kodiak Sciences 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Replimune Group 2 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals & insiders believe in KOD or REPL? 89.1% of Kodiak Sciences shares are owned by institutional investors. Comparatively, 92.5% of Replimune Group shares are owned by institutional investors. 45.3% of Kodiak Sciences shares are owned by insiders. Comparatively, 8.8% of Replimune Group shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Does the MarketBeat Community prefer KOD or REPL? Replimune Group received 150 more outperform votes than Kodiak Sciences when rated by MarketBeat users. Likewise, 64.02% of users gave Replimune Group an outperform vote while only 27.14% of users gave Kodiak Sciences an outperform vote. CompanyUnderperformOutperformKodiak SciencesOutperform Votes1927.14% Underperform Votes5172.86% Replimune GroupOutperform Votes16964.02% Underperform Votes9535.98% Which has more volatility and risk, KOD or REPL? Kodiak Sciences has a beta of 2.4, meaning that its share price is 140% more volatile than the S&P 500. Comparatively, Replimune Group has a beta of 1.26, meaning that its share price is 26% more volatile than the S&P 500. Is KOD or REPL more profitable? Replimune Group's return on equity of -54.84% beat Kodiak Sciences' return on equity.Company Net Margins Return on Equity Return on Assets Kodiak SciencesN/A -84.52% -45.40% Replimune Group N/A -54.84%-42.97% SummaryReplimune Group beats Kodiak Sciences on 10 of the 16 factors compared between the two stocks. Get Kodiak Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for KOD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KOD vs. The Competition Export to ExcelMetricKodiak SciencesBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$230.00M$3.00B$5.56B$7.82BDividend YieldN/A1.89%5.11%4.22%P/E Ratio-1.1930.4222.5718.48Price / SalesN/A498.92395.64103.60Price / CashN/A168.6838.1834.62Price / Book0.863.206.774.25Net Income-$260.49M-$72.35M$3.22B$248.23M7 Day Performance4.06%1.46%1.46%0.89%1 Month Performance70.31%8.79%3.98%3.53%1 Year Performance23.51%-22.36%16.14%5.09% Kodiak Sciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KODKodiak Sciences4.0488 of 5 stars$4.36+4.8%$9.00+106.4%+35.8%$230.00MN/A-1.1990News CoveragePositive NewsREPLReplimune Group4.1827 of 5 stars$8.77+9.6%$19.43+121.5%+54.0%$675.42MN/A-2.86210Positive NewsNUVBNuvation Bio3.6164 of 5 stars$1.99+0.8%$8.75+340.8%-25.1%$672.28M$7.87M-0.9160Upcoming EarningsCRONCronos Group1.5295 of 5 stars$1.74-1.7%$3.50+101.1%-36.1%$670.61M$117.62M-13.38450Upcoming EarningsPAHCPhibro Animal Health3.343 of 5 stars$16.53-4.4%$19.75+19.5%+11.4%$669.52M$1.11B34.441,860Upcoming EarningsPositive NewsAVBPArriVent BioPharma1.0395 of 5 stars$19.54+7.7%$39.00+99.6%+28.7%$664.67MN/A-7.6040Short Interest ↑News CoveragePositive NewsLENZLENZ Therapeutics1.8655 of 5 stars$24.11+1.2%$46.60+93.3%+79.6%$664.06MN/A-5.05110EOLSEvolus3.8493 of 5 stars$10.38-3.8%$23.75+128.8%-3.1%$660.03M$266.27M-11.41170Upcoming EarningsNews CoveragePositive NewsDNTHDianthus Therapeutics1.6058 of 5 stars$20.45+4.9%$54.33+165.7%+2.3%$656.98M$6.24M-8.1880Upcoming EarningsNews CoveragePositive NewsANABAnaptysBio2.4505 of 5 stars$20.62+0.3%$33.63+63.1%-8.7%$632.35M$91.28M-3.39100Upcoming EarningsNews CoveragePositive NewsXERSXeris Biopharma3.6014 of 5 stars$4.02-2.2%$6.10+51.7%+161.1%$618.84M$203.07M-8.93290Upcoming EarningsNews Coverage Related Companies and Tools Related Companies REPL Competitors NUVB Competitors CRON Competitors PAHC Competitors AVBP Competitors LENZ Competitors EOLS Competitors DNTH Competitors ANAB Competitors XERS Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KOD) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kodiak Sciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kodiak Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy KOD Stock Free KOD Stock Alerts